Tag: Brand, Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Announces That It Has Regained Worldwide Rights to DFA-02
Dr. Reddy’s Laboratories Ltd. announced the termination of the license granted to Armis Biopharma, Inc. (formerly known as CHD Bioscience, Inc.) for its...
Dr. Reddy’s Laboratories launches Hervycta (trastuzumab biosimilar) in India
Dr. Reddy’s Laboratories Ltd. announced that it has launched Hervycta® (Trastuzumab), a biosimilar of Roche’s Herceptin® in India, indicated for the treatment of...
Dr. Reddy’s Laboratories announces launch of Tetrabenazine Tablets in U.S. Market
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it has launchedTetrabenazine Tablets, a therapeutic equivalent generic version of...
